Loading stock data…
$1.16-0.02 (-1.69%)
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer.
MAIA Biotechnology, Inc. in the Healthcare sector is trading at $1.16 with a market capitalization of $82M. Wall Street consensus targets $12.00 (2 analysts), implying a +934.5% move over the next 12 months. The stock is currently near its 52-week low of $0.87, remaining 22.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.11M↓ | -$6.74M↓ | -$3.96M↑ | -$9.36M↓ | -$5.17M |
| Net Income | -$7.94M↓ | -$6.37M↓ | -$3.63M↑ | -$8.90M↓ | -$5.35M |
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical de...